{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:06:26Z","timestamp":1792951586053,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.critrevonc.2024.104520","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:52:25Z","timestamp":1726750345000},"page":"104520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Combined use of radiotherapy and tyrosine kinase inhibitors in the management of metastatic non-small cell lung cancer: A literature review"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-9805","authenticated-orcid":false,"given":"Ioannis","family":"Georgakopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Kouloulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ntoumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Desse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Koukourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andromachi","family":"Kougioumtzopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrianni","family":"Charpidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos N.","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zygogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104520_bib1","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1038\/s41467-022-34889-z","article-title":"Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer","volume":"13","author":"Adua","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2024.104520_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14740338.2017.1300656","article-title":"EGFR TKI combination with immunotherapy in non-small cell lung cancer","volume":"16","author":"Ahn","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.critrevonc.2024.104520_bib3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","article-title":"Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy","volume":"10","author":"Al-Halabi","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib4","article-title":"Complete remission of multiple brain metastases in a patient with EGFR-mutated non-small-cell lung cancer treated with first-line osimertinib without radiotherapy","volume":"2020","author":"Ameku","year":"2020","journal-title":"Case Rep. Oncol. Med"},{"key":"10.1016\/j.critrevonc.2024.104520_bib5","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.3390\/cancers13102394","article-title":"Combining radiation therapy with alk inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer (NSCLC): a clinical and preclinical overview","volume":"13","author":"Antoni","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104520_bib6","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor\u2013mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104520_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","article-title":"2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease","volume":"25","author":"Besse","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib8","first-page":"159","article-title":"Radiotherapy and tyrosine kinase inhibitors in stage iv non-small cell lung cancer: real-life experience","volume":"32","author":"Borghetti","year":"2018","journal-title":"Vivo"},{"key":"10.1016\/j.critrevonc.2024.104520_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12032-016-0811-3","article-title":"Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis","volume":"33","author":"Byeon","year":"2016","journal-title":"Med Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clon.2017.04.035","article-title":"The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis","volume":"29","author":"Chan","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133859","article-title":"Comprehensive molecular analysis of NSCLC; Clinicopathological associations","volume":"10","author":"Chatziandreou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2024.104520_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22957-9","article-title":"The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study","volume":"12","author":"Chen","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2024.104520_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.2002","article-title":"Trends in survival rates of non\u2013small cell lung cancer with use of molecular testing and targeted therapy in Korea, 2010-2020","volume":"6","author":"Chi","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2024.104520_bib14","article-title":"Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer","volume":"12","author":"Chicas-Sett","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib15","doi-asserted-by":"crossref","first-page":"9601","DOI":"10.1158\/0008-5472.CAN-06-2627","article-title":"Non\u2013small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation","volume":"66","author":"Das","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104520_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.21037\/tlcr.2019.06.12","article-title":"EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases","volume":"8","author":"Dong","year":"2019","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104520_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2018.00603","article-title":"Upfront cranial radiotherapy vs. egfr tyrosine kinase inhibitors alone for the treatment of brain metastases from non-small-cell lung cancer: a meta-analysis of 1465 patients","volume":"8","author":"Du","year":"2018","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cllc.2018.09.015","article-title":"Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with egfr mutant metastatic non\u2013small-cell lung cancer (NSCLC)","volume":"20","author":"Elamin","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104520_bib19","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib20","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104520_bib21","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib22","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib24","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2147\/OTT.S300267","article-title":"Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment na\u00efve advanced EGFR-mutant lung adenocarcinoma patients","volume":"14","author":"Hsu","year":"2021","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.critrevonc.2024.104520_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12890-023-02472-x","article-title":"Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Pulm. Med"},{"key":"10.1016\/j.critrevonc.2024.104520_bib26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","article-title":"Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations","volume":"20","author":"Iuchi","year":"2015","journal-title":"Int J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib27","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2016.05.013","article-title":"EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases","volume":"11","author":"Jiang","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK -rearranged non\u2013small-cell lung cancer and brain metastasis","volume":"34","author":"Johung","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104520_bib30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104520_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/14737140.2018.1409623","article-title":"Response to afatinib in treatment-na\u00efve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases","volume":"18","author":"Li","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2024.104520_bib32","first-page":"714","article-title":"Management of brain metastases in tyrosine kinase inhibitor\u2013na\u00efve epidermal growth factor receptor\u2013mutant non\u2013small-cell lung cancer: a retrospective multi-institutional analysis","volume":"69","author":"Magnuson","year":"2016","journal-title":"J\u00a0Clin Oncol 2017;35 JCO"},{"key":"10.1016\/j.critrevonc.2024.104520_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2024.104520_bib34","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer Version 5.2023. n.d. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2024.104520_bib35","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.21037\/jtd-22-536","article-title":"Oligoprogression in non-small cell lung cancer: a narrative review","volume":"14","author":"Nguyen","year":"2022","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2024.104520_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2017.03.010","article-title":"Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib","volume":"108","author":"Patel","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104520_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201425","article-title":"Efficacy of ALK inhibitors on NSCLC brain metastases: a systematic review and pooled analysis of 21 studies","volume":"13","author":"Petrelli","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2024.104520_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104520_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104520_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2011.04.007","article-title":"Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure","volume":"74","author":"Shukuya","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2024.104520_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2024.104520_bib43","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post Hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non\u2013small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104520_bib45","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2024.104520_bib46","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2024.104520_bib47","first-page":"77","article-title":"Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer","volume":"41","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2024.104520_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-021-08228-2","article-title":"Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non\u2013small-cell lung cancer: a propensity-matched retrospective study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2024.104520_bib49","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non\u2013small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib50","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.21037\/tlcr-20-552","article-title":"Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents","volume":"10","author":"Wrona","year":"2021","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104520_bib51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative LOcal Ablative Therapy Improves the Survival of Patients with Synchronous Oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib52","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/neuonc\/noaa281","article-title":"Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial","volume":"23","author":"Yang","year":"2021","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111079","article-title":"Breakthrough in targeted therapy for non-small cell lung cancer","volume":"133","author":"Ye","year":"2021","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104520_bib54","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.18632\/oncotarget.3187","article-title":"Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy","volume":"6","author":"Zeng","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2024.104520_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13014-021-01955-7","article-title":"Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study","volume":"16","author":"Zhai","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104520_bib56","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/j.1349-7006.2009.01190.x","article-title":"Radiosensitizing effects of gefitinib at different administration times in vitro","volume":"100","author":"Zhuang","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2024.104520_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12916-021-02207-x","article-title":"Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases\u2014a multicenter retrospective study","volume":"20","author":"Zou","year":"2022","journal-title":"BMC Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T04:04:00Z","timestamp":1732939440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":57,"alternative-id":["S1040842824002634"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104520","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined use of radiotherapy and tyrosine kinase inhibitors in the management of metastatic non-small cell lung cancer: A literature review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104520"}}